Siemens makes moves on Healthineers IPO, mandates banks

Siemens Healthineers could be valued at up to €40 billion, analysts say.

Siemens has kept us all guessing about the fate of its Healthineers business, saying in March it planned to keep a majority stake in the unit after a spinoff or IPO and hinting in May that Healthineers may go public through a reverse merger instead.

Now, Reuters reports, Siemens has mandated Goldman Sachs, Deutsche Bank and JP Morgan as the lead organizers of a Healthineers IPO, according to a source familiar with the matter.

While the company hasn’t decided yet where to list, one of the sources told Reuters that the New York Stock Exchange, where a number of medtech stocks are listed, would have “an edge” over Frankfurt.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: The top companies in medtech by 2016 revenueSiemens Healthineers

“An IPO of the Healthineers unit would enable Siemens to do share deals when looking at future acquisitions,” one of the sources said.

Siemens, which was already managing its healthcare business separately, rebranded it as Healthineers in 2016. At the time, it said the move would allow it to boost its foothold in medical imaging and molecular diagnostics, as well as to add new offerings, such as managed services and digital services.

The company said in August that it would delay a Healthineers IPO until 2018. Healthineers, which pulled in €579 million ($681 million) during the third quarter, could be valued at as much as €40 billion ($47 billion), Reuters reported.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.